CompletedNCT05321602
LY03010 dose and injection site research in schizophrenia
About this title
Read the official source — NCT05321602Medication studyAges 18–65United States
Understand this study
Who was this study for?
Listed age limits: 18 years to 65 years.
- Listed locations
- Little Rock and 8 more locationsSee all locations and recruitment
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
Study information
Study start dateStarted: September 8, 2021
- Recruitment status
- Completed
- Enrollment listed in the registry
- 89
- Sponsor
- Luye Pharma Group Ltd.
- Sponsor type
- Pharmaceutical company
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
- Locations
- United States
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT05321602
- Official title
Show the full official title
A Randomized, Single-Dose, Open-Label, Parallel-Group Study to Evaluate the Pharmacokinetic Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective Disorder
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Little Rock · Garden Grove · Orange
6 more locations
- Torrance
- Miami Lakes
- Atlanta
- Chicago
- Gaithersburg
- DeSoto
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Luye Pharma Group Ltd., a pharmaceutical company.
Did this study involve medication?
Yes. The study involved medication, including LY03010 156 mg treatment group, deltoid, LY03010 156 mg treatment group, gluteal, LY03010 351 mg treatment group, deltoid and LY03010 351 mg treatment group, gluteal.
Who was this study for?
Listed age limits: 18 years to 65 years.
